Detecting Minimal Residual Disease in Neuroblastoma: The Superiority of a Panel of Real-Time Quantit...
Detecting Minimal Residual Disease in Neuroblastoma: The Superiority of a Panel of Real-Time Quantitative PCR Markers
About this item
Full title
Author / Creator
Publisher
Washington, DC: Am Assoc Clin Chem
Journal title
Language
English
Formats
Publication information
Publisher
Washington, DC: Am Assoc Clin Chem
Subjects
More information
Scope and Contents
Contents
Background: PCR-based detection of minimal residual disease (MRD) in neuroblastoma (NB) patients can be used for initial staging and monitoring therapy response in bone marrow (BM) and peripheral blood (PB). PHOX2B has been identified as a sensitive and specific MRD marker; however, its expression varies between tumors. Therefore, a panel of marker...
Alternative Titles
Full title
Detecting Minimal Residual Disease in Neuroblastoma: The Superiority of a Panel of Real-Time Quantitative PCR Markers
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_67424437
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_67424437
Other Identifiers
ISSN
0009-9147
E-ISSN
1530-8561
DOI
10.1373/clinchem.2008.117945
